ClinicalTrials.gg
Sign In

Clear-cell metastatic renal cell carcinoma clinical trials

The registry lists 70 studies for Clear-cell metastatic renal cell carcinoma across more than 10 countries. 31 are recruiting or about to start. 57 of them are mainly about Clear-cell metastatic renal cell carcinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04.

Get an email when these change. Save the Clear-cell metastatic renal cell carcinoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting
25
Completed
20
Terminated
10
Not yet recruiting
5
Active, not recruiting
5
Withdrawn
3

Phase

Phase 2
40
Phase 1
26
Phase 3
4
Early Phase 1
3
Phase 4
2

Where

United States
38
France
12
Canada
8
China
8
Spain
6
Italy
6

Who runs them

City of Hope Medical Center (4) · M.D. Anderson Cancer Center (3) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (3) · Radboud University Medical Center (2) · University of Texas Southwestern Medical Center (2) · Vanderbilt-Ingram Cancer Center (2) · Celldex Therapeutics (2) · Pfizer (2)

What is being tested here

Drugs under test in Clear-cell metastatic renal cell carcinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Nivolumab207
Clostridium butyricum miyairi 588 strain213
Zanzalintinib202
Casdatifan212
Cabozantinib202
Axitinib103
Ipilimumab103
Pembrolizumab102
Toripalimab101
Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open · Immune checkpoint inhibitors 5 open

Coming up

3phase 3 studies under way
13studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 25 Clear-cell metastatic renal cell carcinoma studies recruiting now, 22 (88%) set no upper age limit and 1 (4%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 25
AgeWomenMen
100 (0%)0 (0%)
1825 (100%)25 (100%)
3025 (100%)25 (100%)
4025 (100%)25 (100%)
5025 (100%)25 (100%)
6525 (100%)25 (100%)
7525 (100%)25 (100%)
8524 (96%)24 (96%)

Across all 70 studies, recruiting or not: 7% stop at 75 or younger and 0% at 65; 1% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 15, 2026.

Stopped1

Studies

Recruiting first, then most recently updated. Showing 50 of 70. Browse all 70 → or search them.